Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
ELISA Kit for Acid Phosphatase 5, Tartrate Resistant (ACP5)
TRAP; TrATPase; Tartrate Resistant Acid Phosphatase; Type 5 acid phosphatase
- Product No.SEA902Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3h
- Detection Range0.312-20ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.129ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 441
For more details, please contact local distributors! US$ 630 US$ 2835 US$ 5355 US$ 44100
Specificity
This assay has high sensitivity and excellent specificity for detection of Acid Phosphatase 5, Tartrate Resistant (ACP5).
No significant cross-reactivity or interference between Acid Phosphatase 5, Tartrate Resistant (ACP5) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Acid Phosphatase 5, Tartrate Resistant (ACP5) and the recovery rates were calculated by comparing the measured value to the expected amount of Acid Phosphatase 5, Tartrate Resistant (ACP5) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 97-104 | 101 |
EDTA plasma(n=5) | 89-96 | 92 |
heparin plasma(n=5) | 78-95 | 83 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Acid Phosphatase 5, Tartrate Resistant (ACP5) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Acid Phosphatase 5, Tartrate Resistant (ACP5) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Acid Phosphatase 5, Tartrate Resistant (ACP5) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 91-98% | 80-92% | 78-104% | 89-103% |
EDTA plasma(n=5) | 99-105% | 90-99% | 88-102% | 89-101% |
heparin plasma(n=5) | 85-101% | 81-101% | 84-101% | 97-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
- Single-component Reagents of Assay Kit
- Lysis Buffer Specific for ELISA / CLIA
- Quality Control of Kit
- ELISA Kit Customized Service
- Disease Model Customized Service
- Serums Customized Service
- TGFB1 Activation Reagent
- Real Time PCR Experimental Service
- Streptavidin
- Fast blue Protein Stain solution
- Single-component Reagents of FLIA Kit
- Streptavidin-Agarose Beads
Magazine | Citations |
Archives of Oral Biology | Oxytocin promotes bone formation during the alveolar healing process in old acyclic female rats ScienceDirect: S0003996912001021 |
Life Sciences | Exendin-4 Increases Bone Mineral Density in Type 2 Diabetic OLETF Rats Potentially Through the Down-Regulation of SOST/Sclerostin in Osteocytes PubMed: 23357248 |
International Journal of Cardiology | Valvular osteoclasts in calcification and aortic valve stenosis severity. Pubmed: 23452891 |
Evidence-Based Complementary and Alternative Medicine | Antiosteoporosis Activity of New Oriental Medicine Preparation (Kyungokgo Mixed with Water Extract of Hovenia dulcis) on the Ovariectomized Mice Pubmed:25737735 |
Advances in Medical Sciences | The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats PubMed: 26569440 |
Bone | The effects of strength training and raloxifene on bone health in aging ovariectomized rats Pubmed:26812611 |
Journal of Clinical Medicine Research | In Vitro and In Vivo Effects of Gracilaria verrucosa Extracts on Osteoclast Differentiation. pubmed:28335442 |
Biomedicine & Pharmacotherapy | Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats S0753332216322752 |
Clinical Trials in Degenerative Diseases | Correlating oxidative stress-related factors with bone metabolic markers in older adult male patients exhibiting degenerative osteoporosis in the high-altitude hypoxic area of China: study protocol for a non-randomized controlled trial issn:2542-3975 |
Scientific Reports | Evidence for excessive osteoclast activation in SIRT6 null mice Pubmed:30030453 |
International Journal of Molecular Sciences | Suppression Effect of Astaxanthin on Osteoclast Formation In Vitro and Bone Loss In Vivo Pubmed:29562730 |
Experimental Gerontology | The decline of whole-body glucose metabolism in ovariectomized rats Pubmed: 30292771 |
Bone Research | NUMB maintains bone mass by promoting degradation of PTEN and GLI1 via ubiquitination in osteoblasts Pubmed: 30455992 |
Cell Death & Disease | QKI deficiency leads to osteoporosis by promoting RANKL-induced osteoclastogenesis and disrupting bone metabolism Pubmed: 32382069 |
Effect of Corticopuncture (CP), Photobiomodulation (PBM) and the Combined Method on the Rate of Tooth Movement and Root Resorption: A Molecular, Histological … | |
Evid Based Complement Alternat Med | Gujiansan Ameliorates Avascular Necrosis of the Femoral Head by Regulating Autophagy via the HIF-1α/BNIP3 Pathway 34512780 |
Catalog No. | Related products for research use of Homo sapiens (Human) Organism species | Applications (RESEARCH USE ONLY!) |
RPA902Hu01 | Recombinant Acid Phosphatase 5, Tartrate Resistant (ACP5) | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA902Hu01 | Polyclonal Antibody to Acid Phosphatase 5, Tartrate Resistant (ACP5) | WB; IHC; ICC; IP. |
MAA902Hu22 | Monoclonal Antibody to Acid Phosphatase 5, Tartrate Resistant (ACP5) | WB; IHC; ICC; IP. |
SEA902Hu | ELISA Kit for Acid Phosphatase 5, Tartrate Resistant (ACP5) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA902Hu | Multiplex Assay Kit for Acid Phosphatase 5, Tartrate Resistant (ACP5) ,etc. by FLIA (Flow Luminescence Immunoassay) | FLIA Kit for Antigen Detection. |